Hodgkin Lymphoma — Trials

Hodgkin Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 179
Recruiting: 90
Ph III recruiting: 6
Growth YoY: −4.2%
Industry share: 11%
Top sponsor: City of Hope Medical Center
Termination share: 27.7%
Trials / 1,000 deaths: 175.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (145)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07572123	Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem Cell Transplant Alone for High-risk Patients With Relapsed or Refractory Hodgkin Lymphoma	not yet recruiting	Phase 2 / Phase 3	374	National Cancer Institute (NCI)NIH	0	Jul 8, 2026	clinicaltrials
NCT06465446	A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma	not yet recruiting	Phase 3	202	ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER